Exercise prevents raphe nucleus mitochondrial overactivity in a rat depression model

Physiology and Behavior

Volumn 132, Issue , 2014, Pages 57-65

  Wen, Li ^a   Jin, Yahong ^a   Li, Lei ^a   Sun, Shuangyu ^a   Cheng, Shixiang ^b   Zhang, Sai ^b   Zhang, Yong ^a   Svenningsson, Per ^c  

^a TIANJIN UNIVERSITY OF SPORT   (China)

^b Logistics College of Chinese Armed Police Forces   (China)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chronic unpredictable stress; Exercise; Fluoxetine; Mitochondrial function; Serotonin

Indexed keywords

ADENOSINE TRIPHOSPHATE; FLUOXETINE; GLUTATHIONE PEROXIDASE; SEROTONIN; SUPEROXIDE DISMUTASE; ANTIDEPRESSANT AGENT; MITOCHONDRIAL PROTEIN; SUCROSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; BODY WEIGHT; CONTROLLED STUDY; DEPRESSION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENZYME ACTIVITY; EXERCISE; HIPPOCAMPUS; MALE; MITOCHONDRIAL RESPIRATION; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; RAPHE NUCLEUS; RAT; RESPIRATION CONTROL; STRESS; SUCROSE PREFERENCE TEST; TREADMILL EXERCISE; ANALYSIS OF VARIANCE; ANIMAL; BRAIN; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; EXPLORATORY BEHAVIOR; FOOD PREFERENCE; METABOLISM; MITOCHONDRIAL DISEASES; MITOCHONDRION; PATHOLOGY; PROCEDURES; SPRAGUE DAWLEY RAT;

ADENOSINE TRIPHOSPHATE; ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; EXPLORATORY BEHAVIOR; FLUOXETINE; FOOD PREFERENCES; GLUTATHIONE PEROXIDASE; MALE; MITOCHONDRIA; MITOCHONDRIAL DISEASES; MITOCHONDRIAL PROTEINS; PHYSICAL CONDITIONING, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SUCROSE; SUPEROXIDE DISMUTASE;

EID: 84900835970     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2014.04.050     Document Type: Article

References (52)

1. Organization, WH. Depression: a global public health concern. Health WpwftWFoM 2012, [editor].
2. López-Muñoz F., Alamo C. Monoaminergic neurotransmission: the history of the discovery of antidepressants from 1950s until today. Curr. Pharm. Des. 2009, 15:1563-1586.
3. Bauer M., Bschor T., Pfennig A., Whybrow P.C., Angst J., Versiani M., et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders in primary care. World J. Biol. Psychiatry 2007, 8:67-104.
4. Einarson T.R., Arikian S.R., Casciano J., Doyle J.J. Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic antidepressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin. Ther. 1999, 21:296-308.
5. Guaiana G., Barbui C., Hotopf M. Amitriptyline for depression. Cochrane Database Syst. Rev. 2007, 3.
6. Nutt D.J. The neuropharmacology of serotonin and noradrenaline in depression. Int. Clin. Psychopharmacol. 2002, 17(Suppl. 1):S1-S12.
7. Usala T., Clavenna A., Zuddas A., Bonati M. Randomised controlled trials of selective serotonin reuptake inhibitors in treating depression in children and adolescents: a systematic review and meta-analysis. Eur. Neuropsychopharmacol. 2008, 18:62-73.
8. Timonen M., Liukkonen T. Management of depression in adults. BMJ 2008, 336:435-439.
9. Marazziti D., Baroni S., Picchetti M., Landi P., Silvestri S., Vatteroni E., et al. Mitochondrial alterations and neuropsychiatric disorders. Curr. Med. Chem. 2011, 18:4715-4721.
10. Gardner A., Boles R.G. Beyond the serotonin hypothesis: mitochondria, inflammation and neurodegeneration in major depression and affective spectrum disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:730-743.
11. Maes M., Fisar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012, 20:127-150.
12. Jou S.H., Chiu N.Y., Liu C.S. Mitochondrial dysfunction and psychiatric disorders. Chang Gung Med. J. 2009, 32:370-379.
13. Carek P.J., Laibstain S.E., Carek S.M. Exercise for the treatment of depression and anxiety. Int. J. Psychiatry Med. 2011, 41:15-28.
14. Dinas P.C., Koutedakis Y., Flouris A.D. Effects of exercise and physical activity on depression. Ir. J. Med. Sci. 2011, 180:319-325.
15. Rimer J., Dwan K., Lawlor D.A., Greig C.A., McMurdo M., Morley W., et al. Exercise for depression. Cochrane Database Syst. Rev. 2012, 7. [CD004366].
16. Blumenthal J.A., Babyak M.A., Doraiswamy P.M., Watkins L., Hoffman B.M., Barbour K.A., et al. Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom. Med. 2007, 69:587-596.
17. Hoffman B.M., Babyak M.A., Craighead W.E., Sherwood A., Doraiswamy P.M., Coons M.J., et al. Exercise and pharmacotherapy in patients with major depression: one-year follow-up of the SMILE study. Psychosom. Med. 2011, 73:127-133.
18. Zheng H., Liu Y., Li W., Yang B., Chen D., Wang X., et al. Beneficial effects of exercise and its molecular mechanisms on depression in rats. Behav. Brain Res. 2006, 168:47-55.
19. Liu W., Zhou C. Corticosterone reduces brain mitochondrial function and expression of mitofusin, BDNF in depression-like rodents regardless of exercise preconditioning. Psychoneuroendocrinology 2012, 37:1057-1070.
20. Hamon M., Blier P. Monoamine neurocircuitry in depression and strategies for new treatments. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 45:54-63.
21. Michelsen K.A., Prickaerts J., Steinbusch H.W. The dorsal raphe nucleus and serotonin: implications for neuroplasticity linked to major depression and Alzheimer's disease. Prog. Brain Res. 2008, 172:233-264.
22. Murua V.S., Gomez R.A., Andrea M.E., Molina V.A. Shuttle-box deficits induced by chronic variable stress: reversal by imipramine administration. Pharmacol. Biochem. Behav. 1991, 38:125-130.
23. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berlin) 1987, 93:358-364.
24. Fulk L.J., Stock H.S., Lynn A., Marshall J., Wilson M.A., Hand G.A. Chronic physical exercise reduces anxiety-like behavior in rats. Int. J. Sports Med. 2004, 25:78-82.
25. Burghardt P.R., Fulk L.J., Hand G.A., Wilson M.A. The effects of chronic treadmill and wheel running on behavior in rats. Brain Res. 2004, 1019:84-96.
26. Helmich I., Latini A., Sigwalt A., Carta M.G., Machado S., Velasques B., et al. Neurobiological alterations induced by exercise and their impact on depressive disorders [corrected]. Clin. Pract. Epidemiol. Ment. Health 2010, 6:115-125.
27. Fang Z.H., Lee C.H., Seo M.K., Cho H., Lee J.G., Lee B.J., et al. Effect of treadmill exercise on the BDNF-mediated pathway in the hippocampus of stressed rats. Neurosci. Res. 2013, 76:187-194.
28. Bedford T.G., Tipton C.M., Wilson N.C., Oppliger R.A., Gisolfi C.V. Maximum oxygen consumption of rats and its changes with various experimental procedures. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 1979, 47:1278-1283.
29. Kennett G.A., Dickinson S.L., Curzon G. Enhancement of some 5-HT-dependent behavioural responses following repeated immobilization in rats. Brain Res. 1985, 330:253-263.
30. Singh I.N., Sullivan P.G., Hall E.D. Peroxynitrite-mediated oxidative damage to brain mitochondria: protective effects of peroxynitrite scavengers. J. Neurosci. Res. 2007, 85:2216-2223.
31. Vaishnav R.A., Singh I.N., Miller D.M., Hall E.D. Lipid peroxidation-derived reactive aldehydes directly and differentially impair spinal cord and brain mitochondrial function. J. Neurotrauma 2010, 27:1311-1320.
32. Paxinos G., Watson C. The rat brain: in stereotoxic coordinates 1998, Academic Press, San Diego.
33. Chamas F.M., Underwood M.D., Arango V., Serova L., Kassir S.A., Mann J.J., et al. Immobilization stress elevates tryptophan hydroxylase mRNA and protein in the rat raphe nuclei. Biol. Psychiatry 2004, 55:278-283.
34. Yamamura S., Abe M., Nakagawa M., Ochi S., Ueno S., Okada M. Different actions for acute and chronic administration of mirtazapine on serotonergic transmission associated with raphe nuclei and their innervation cortical regions. Neuropharmacology 2011, 60:550-560.
35. Barksdale K.A., Perez-Costas E., Gandy J.C., Melendez-Ferro M., Roberts R.C., Bijur G.N. Mitochondrial viability in mouse and human postmortem brain. FASEB J. 2010, 24:3590-3599.
36. Medeiros R., Prediger R.D., Passos G.F., Pandolfo P., Duarte F.S., Franco J.L., et al. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. J. Neurosci. 2007, 27:5394-5404.
37. Yang Y., Xia X., Zhang Y., Wang Q., Li L., Luo G., et al. delta-Opioid receptor activation attenuates oxidative injury in the ischemic rat brain. BMC Biol. 2009, 7:55.
38. El-Ansary A.K., Ben Bacha A., Kotb M. Etiology of autistic features: the persisting neurotoxic effects of propionic acid. J. Neuroinflammation 2012, 9:74.
39. Bambico F.R., Nguyen N.T., Gobbi G. Decline in serotonergic firing activity and desensitization of 5-HT1A autoreceptors after chronic unpredictable stress. Eur. Neuropsychopharmacol. 2009, 19:215-228.
40. Cox B.M., Alsawah F., McNeill P.C., Galloway M.P., Perrine S.A. Neurochemical, hormonal, and behavioral effects of chronic unpredictable stress in the rat. Behav. Brain Res. 2011, 220:106-111.
41. Liu Q., Yu J., Mao-Ying Q.L., Mi W.L., Li B., Wang Y.Q., et al. Repeated clomipramine treatment reversed the inhibition of cell proliferation in adult hippocampus induced by chronic unpredictable stress. Pharmacogenomics J. 2008, 8:375-383.
42. Luo D.D., An S.C., Zhang X. Involvement of hippocampal serotonin and neuropeptide Y in depression induced by chronic unpredicted mild stress. Brain Res. Bull. 2008, 77:8-12.
43. Marona-Lewicka D., Nichols D.E. The effect of selective serotonin releasing agents in the chronic mild stress model of depression in rats. Stress 1997, 2:91-100.
44. Ahmad A., Rasheed N., Banu N., Palit G. Alterations in monoamine levels and oxidative systems in frontal cortex, striatum, and hippocampus of the rat brain during chronic unpredictable stress. Stress 2010, 13:355-364.
45. Moretti M., Colla A., de Oliveira Balen G., dos Santos D.B., Budni J., de Freitas A.E., et al. Ascorbic acid treatment, similarly to fluoxetine, reverses depressive-like behavior and brain oxidative damage induced by chronic unpredictable stress. J. Psychiatr. Res. 2012, 46:331-340.
46. Johnson B.N., Yamamoto B.K. Chronic unpredictable stress augments +3,4-methylenedioxymethamphetamine-induced monoamine depletions: the role of corticosterone. Neuroscience 2009, 159:1233-1243.
47. Lopez J.F., Chalmers D.T., Little K.Y., Watson S.J. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol. Psychiatry 1998, 43:547-573.
48. Joels M., Verkuyl J.M., Van Riel E. Hippocampal and hypothalamic function after chronic stress. Ann. N. Y. Acad. Sci. 2003, 1007:367-378.
49. Krugers H.J., Lucassen P.J., Karst H., Joels M. Chronic stress effects on hippocampal structure and synaptic function: relevance for depression and normalization by anti-glucocorticoid treatment. Front. Synaptic Neurosci. 2010, 2:24.
50. Rainer Q., Nguyen H.T., Quesseveur G., Gardier A.M., David D.J., Guiard B.P. Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration. Mol. Pharmacol. 2012, 81:106-112.
51. He S.B., Tang W.G., Tang W.J., Kao X.L., Zhang C.G., Wong X.T. Exercise intervention may prevent depression. Int. J. Sports Med. 2012, 33:525-530.
52. Moon H.Y., Kim S.H., Yang Y.R., Song P., Yu H.S., Park H.G., et al. Macrophage migration inhibitory factor mediates the antidepressant actions of voluntary exercise. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:13094-13099.